Clinical Trial Detail

NCT ID NCT02899078
Title Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors University of California, Davis
Indications

kidney cancer

Therapies

Ibrutinib + Nivolumab

Age Groups: senior adult

No variant requirements are available.